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PURPOSE. To evaluate the safety and efficacy of high-intensity focused ultrasound (HIFU)
cyclocoagulation in reducing intraocular pressure (IOP) in patients with refractory glaucoma
by using a novel miniaturized delivery device (EyeOP1).
METHODS. We conducted a 12-month open-label multicenter prospective study (EyeMUST1
Study). Patients with primary (primary open-angle glaucoma [POAG]) or secondary refractory
glaucoma were treated in two groups depending on the duration of each ultrasound shot
(group 1: 4 seconds; group 2: 6 seconds). The primary efficacy outcome was based on IOP
reduction at 6 and 12 months.
RESULTS. Fifty-two patients were enrolled: 36 (69%) had POAG and 16 (31%) had secondary
glaucoma. Group 1 (n ¼ 24) and group 2 (n ¼ 28) had similar demographics and baseline
characteristics. In group 1, IOP was reduced from a mean preoperative value of 29.7 6 7.7
mm Hg (n ¼ 3.5 glaucoma medications) to a mean postoperative value of 21.3 6 6.7 mm Hg
(n ¼ 3.5 glaucoma medications) and 20.1 6 6.7 mm Hg (n ¼ 3.2 glaucoma medications) at 6
and 12 months, respectively. In group 2, IOP was reduced from a mean preoperative value of
29.0 6 7.4 mm Hg (n ¼ 3.3 glaucoma medications) to a mean postoperative value of 20.2 6
7.4 mm Hg (n ¼ 3.4 glaucoma medications) and 18.5 6 6.6 mm Hg (n ¼ 3.5 glaucoma
medications) at 6 and 12 months, respectively. At 12 months, the IOP reduction was sustained
in both groups (32% IOP reduction in group 1 and 36% IOP reduction in group 2). The overall
tolerance of the technique was good, with no serious adverse events.
CONCLUSIONS. The new miniaturized HIFU EyeOP1 delivery device seems to be effective in
decreasing IOP in patients with refractory glaucoma. The technology offers a good safety
profile. (ClinicalTrials.gov number, NCT01338467.)
Keywords: ciliary body/ultrasonography, glaucoma/therapy, intraocular pressure,
miniaturization/methods, treatment outcome
Intraocular pressure (IOP) reduction is the only glaucomatherapy proven to be effective. It has been shown to delay or
prevent the development of glaucoma in eyes with ocular
hypertension1 and to prevent progression of glaucoma in eyes
with and without elevated IOP.2,3 Intraocular pressure reduc-
tion can be achieved by topical and systemic medications,
various laser therapies, and a number of incisional surgical
techniques. These approaches aim to reduce IOP through a
better balance between aqueous humor inflow and outflow:
increasing outflow and/or decreasing inflow, that is, aqueous
humor production.
Diode laser cyclophotocoagulation (CPC) is considered to
be the current ciliary body ablation technique to lower IOP.4
Historical methods, such as diathermy and cryotherapy, have
been used with poor visual status and are associated with
serious and vision-impairing complications.4,5
Laser diode cycloablation has been shown to be reasonably
effective but may cause destruction of surrounding ocular
tissues, with a significant risk of chronic ocular hypotony,
phthisis, uveal inflammation, and retinal detachment.4–10
To selectively destroy ciliary body tissue, high-intensity
focused ultrasound (HIFU) was introduced first in the United
States by Coleman et al.11 (Sonocare Therapeutic Ultrasound
System; Sonocare, Inc., Ridgewood, NJ, USA) and later in
Europe. Positive outcomes decreasing IOP have been report-
ed.11–13 Compared to lasers, ultrasound beams can be focused
through optically opaque ocular media with controlled energy
absorption, thereby minimizing the impact upon adjacent
structures, and their effect does not depend on the degree of
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pigmentation of the ciliary body. Despite being effective in
reducing IOP, the former HIFU procedure is burdensome,
requiring up to 2 hours in the operating room11,14 and is
technically challenging owing to a rather bulky delivery system
and the complex management of multiple confluent impacts.
Moreover, the procedure is associated with a relatively high
rate of ocular complications, probably due to the inaccurate
positioning of the bulky probe. Furthermore, the relatively low
frequency of the device (5 MHz) creates a much wider focal
zone, thus potentially damaging more tissue than neces-
sary.15,16
Leveraging recent advances in the technology, a new
cyclocoagulation device, the EyeOP1 (EyeTechCare, Rillieux-
la-Pape, France), using miniaturized transducers to produce
HIFU, has been developed. The device has previously been
described in detail.16–18 Several technical improvements have
been made to the previous ultrasound technology, providing
simpler, safer, faster, and more precise treatment. More
specifically, the therapy probe is placed in direct contact with
the ocular surface. The entire treatment is conducted with no
need to modify the settings, which significantly reduces the
procedure time (approximately 2 minutes) and minimizes the
risk of operator errors. The rapid sequential activation of the
miniaturized transducers delivers six focused ultrasound beams
to induce partial and well-controlled lesions corresponding to
six segments of linear tissue coagulation in the ciliary body
(cyclocoagulation). The higher operating frequency (21 MHz)
than that of the Sonocare system (5 MHz) allows for a sharper
transition between the focal zone and adjacent untreated
tissue. The result is a highly precise focusing of the HIFU target
zone, not exceeding 0.1 mm 3 1 mm, enhanced by
preoperative high-resolution modeling of the ocular structures.
The treatment parameters include a 21-MHz frequency, 2.45-W
acoustic power, with the activation of each transducer lasting 4
or 6 seconds, depending on patient groups. The HIFU probe is
supplied in three sizes (11, 12, and 13 mm), which fit most
ocular sizes and, for every patient, the choice of the right size is
based directly on ultrasound biomicroscopy (UBM) preopera-
tive biometric data.17
Animal studies using the EyeOP1 device have shown a
reduction in IOP with good local tolerance, confirmed by
histologic examination.18 Subsequently, a pilot clinical study in
12 refractory glaucoma patients was conducted, showing a
significant IOP reduction with no major intra- or postoperative
complications, using 3- and 4-second treatment times.17 Based
on the results of the pilot study, a new dose-escalation study
was conducted with 4- and 6-second treatment times, mainly to
compare the efficacy results and safety profile with the two
exposure times.
PATIENTS AND METHODS
Fifty-two patients with primary and secondary glaucoma of
various etiologies (Table 1), including primary open-angle
glaucoma (POAG) with a history of previous failed filtering
surgery, pigmentary glaucoma, and pseudo-exfoliation glauco-
ma, were recruited from nine French clinical sites under a
prospective open-label study of the EyeOP1 device (Table 1).
The EyeMUST1 study was registered on ClinicalTrials.gov
under the identifying number NCT01338467. The study was
conducted in compliance with the Declaration of Helsinki, ISO
14155:2011: Clinical Investigations of Medical Devices for
Human Subjects—Good Clinical Practices, and after approval
from relevant ethics committees and the competent authori-
ties. All patients provided written informed consent before
enrollment. Eligibility criteria included men or women 18 years
or older, IOP > 21 mm Hg under maximum medical therapy,
with at least one failed filtering surgery. Patients included in the
study had not had surgical or laser treatment within the 3
months preceding the study treatment, and no previous ciliary
body interventions or drainage implants were included.
Additionally, prior hypotensive treatments were maintained
throughout the study period. Only one eye per patient was
eligible for enrollment.
Two consecutive groups of patients treated with two
different exposure times were included. The patients in group
1 were treated with a 4-second insonification exposure time
and the patients in group 2 were treated with a 6-second
exposure time.
The 4-second exposure time was the dose used in the initial
pilot study, showing an acceptable compromise in terms of
efficacy and safety. To confirm the results of the pilot study on
a broader population with a greater number of centers
involved, this study started at the 4-second exposure time.
The dose-escalation design was planned to allow the HIFU
duration to be increased from 4 to 6 seconds after a 1-month
interim review of the results of the first pool of patients by the
investigator committee. Based on preclinical studies, increas-
ing the HIFU delivery time from 4 to 6 seconds was intended to
increase the volume of ciliary process destruction from 4.8
mm3 to 7.8 mm3 each, and therefore to increase the overall
effect on inflow reduction.15,16
The study lasted 1 year, with the primary effectiveness
endpoint evaluated at 6 and 12 months. Postoperative visits
occurred at 1 day, 1 week, and then 1, 2, 3, 6, and 12 months.
The ocular examination included slit-lamp and fundus exam-
ination, Snellen best corrected visual acuity (BCVA), central
visual field, ultrasonic corneal pachymetry, gonioscopy, preop-
erative axial length measurement, UBM, and optical coherence
tomography (AC Visante OCT; Carl Zeiss Meditec AG, Jena,
Germany) examinations. Intraocular pressure, measured with
Goldman applanation tonometry, was requested to be taken
within 63 hours of the preoperative examination time. The
use of hypotensive medication and any adverse events were
recorded at each visit. As per protocol, the glaucoma
medication remained unchanged for the 2 months following
TABLE 1. Patient Demographics
N (%) Group 1 Group 2 P Value
Patients 24 28
Age, mean (range), y 63.8 (40–89) 62.5 (37–88) NS
Sex 1.00*
Female 12 (50.0) 14 (50.0)
Male 12 (50.0) 14 (50.0)
Ethnicity 0.123†
Caucasian 18 (75.0) 26 (92.8)
Black 6 (25.0) 2 (7.2)
Type of glaucoma 0.313†
Primary open-angle 14 (58.3) 22 (78.6)
Uveitic 3 (12.5) 0
Exfoliative 1 (4.2) 2 (7.1)
Pigmentary 1 (4.2) 0
Traumatic 1 (4.2) 0
Aphakic 1 (4.2) 1 (3.6)
Others 3 (12.5) 3 (10.7)
Juvenile 2 0
Chandler syndrome 1 0
Ocular toxoplasmosis 0 1
Angle-closure glaucoma 0 2
* v2 test.
† Fisher test.
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the study procedure. After the 2-month period, if necessary, an
adjustment of the patient’s medication was allowed. Also, after
2 months, retreatment was allowed for patients with either IOP
remaining above 28 mm Hg despite initial treatment efficacy,
that is, a >20% reduction, or for patients who did not
experience a 20% decrease versus preoperative values.
HIFU Procedure
Patients were treated under peribulbar anesthesia, general
anesthesia, or topical anesthesia combined with short sedation,
according to each center’s specific preferences. All the
investigators were carefully trained in the EyeOP1 procedure
(Fig. 1). To focus the ablation in the ciliary body, the HIFU
probe size was selected on the basis of anatomy of each eye,
assessed in all patients by UBM ultrasonography of the anterior
segment. Moreover, in several equipped centers, a Visante AS-
OCT examination was done (25/54 patients), but the OCT
results were not used to determine probe size. All probe sizes
were selected in the study management center by a single
operator using a proprietary computer-assisted overlay draw-
ing method performed by the EyeOP1 manufacturer. Three
device models with different ring diameters, equipped with
the six transducers, were available. Depending on the
diameter, the six elliptical cylinder-shaped volumes were
centered on an 11-, 12-, or 13-mm-diameter circle. After sizing,
the probe was manually centered on the patient’s eye and held
in place by a mild suction system during the sequential
activation of the six sectors.
In addition to the pressure-lowering preoperative treatment
requested to be maintained for the first 2 months after the
HIFU procedure, postoperative treatments as per protocol
included flurbiprofen (Ocufen; Allergan, Irvine, CA, USA) or a
combination of dexamethasone and tobramycin (Tobradex;
Alcon Laboratories, Inc., Fort Worth, TX, USA) given four times
daily for 1 month.
Outcome Measures and Statistical Analysis
The primary efficacy outcome was based on IOP reduction at 6
and 12 months. Surgical success (patients considered to be
responders) was IOP reduction from baseline ‡ 20% and final
IOP > 5 mm Hg without adding hypotensive medications and
with possible HIFU retreatment.
Secondary endpoints were intra- and postoperative toler-
ance and visual acuity. Other study outcomes included IOP and
medication use results, and complication rates.
The key outcome measures are presented by using
descriptive statistics. The Student’s t-test was used to compare
means and percentages; statistical significance was set at P <
0.05. Owing to the descriptive nature of the statistical analysis,
no imputations of missing data were performed, and the
analyses used only observed data.
The study protocol design stated that in case an additional
treatment, such as filtering surgery or cyclodestruction (CPC
laser or cryotherapy), was administered to a patient to lower
ocular pressure, the patient would be considered as having
failed the HIFU treatment (failure). Efficacy data (IOP values)
FIGURE 1. Top left: High-intensity focused ultrasound device comprising two elements: the probe (left) with the six piezoelectric elements
(transducers) generating the ultrasound beam, and the positioning cone (right). Bottom left: The cone in place showing a ring of visible sclera;
when this ring is regular, the position is correct and then maintained by a mild vacuum system. Bottom right: The probe has been inserted in the
cone and the device has been filled with physiological solution via the well in the middle. The treatment can start.
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would not be collected and integrated into the results for
patients withdrawn from the study after undergoing filtering
surgery or CPC treatment by diode laser so as not to bias the
results.
RESULTS
Demographics
Fifty-two (52) patients were enrolled in the study (Fig. 2): 24
were treated with the 4-second dose (group 1) and 28 with the
6-second dose (group 2). Demographic data are reported in
Table 1. The HIFU procedure was incomplete for two patients:
one experienced chemosis, impairing the ability to deliver the
planned treatment, and for another patient, only four of the six
planned sectors were treated. Nevertheless, these two patients
were included in the efficacy and safety analysis. The
enrollment rate between the two groups was overall evenly
distributed across the sites. Only one eye per patient was
treated.
Table 2 presents the ocular characteristics of the population
before the study treatment, per study group.
All HIFU procedures were performed by 10 surgeons, under
local anesthesia (n ¼ 38), topical with sedation (n ¼ 7), or
general (n¼ 7) anesthesia depending on patient and physician
preference. Forty-four patients had only one HIFU procedure
and eight patients had two HIFU procedures.
Efficacy in All Patients
The efficacy results include the patients who were re-treated as
planned as per protocol for five (5/24) patients in group 1 and
three (3/28) patients in group 2.
The effect of the HIFU procedure on IOP was clinically
significant for both groups (Table 3).
At 6 months, IOP was significantly reduced in group 1 from
29.7 mm Hg (SD, 7.7 mm Hg) to 21.3 mm Hg (SD, 6.7 mm Hg),
corresponding to a mean reduction of 28.3%; and in group 2
from 29.0 mm Hg (SD, 7.4 mm Hg) to 20.2 mm Hg (SD, 7.4 mm
Hg), corresponding to a mean IOP reduction of 30.2%. These
results were obtained with virtually no change in glaucoma
medication in either group.
At 12 months, IOP reduction was sustained in both groups
with a mean IOP of 20.1 mm Hg (SD, 6.7 mm Hg) in group 1
(corresponding to a mean reduction of 32.2%) and a mean IOP
of 18.5 mm Hg (SD, 6.6 mm Hg) in group 2 (corresponding to a
mean reduction of 36.0%) (Fig. 3).
Success, defined as a greater than 20% IOP decrease and
IOP > 5 mm Hg was achieved at 6 months in 61.9% (13/21) of
the patients in group 1 and 65.4% (17/26) of the patients in
group 2. At 12 months, this proportion was 57.1% in group 1
(12/21) and 48.0% in group 2 (12/25). This difference was not
statistically significant (Fisher test, P value ¼ 0.56).
Efficacy in POAG Patients
The success rate of the POAG subgroups significantly differed
from that observed in the overall population (Table 4).
At 6 months, IOP was significantly reduced in group 1
POAG patients from 28.0 mm Hg (SD, 5.0 mm Hg) to 20.3 mm
Hg (SD, 5.7 mm Hg), corresponding to a mean IOP reduction
of 27.5%; and in group 2 POAG patients, from 28.7 mm Hg (SD,
6.8 mm Hg) to 18.8 mm Hg (SD, 5.1 mm Hg), corresponding to
a mean IOP reduction of 34.5%. These results were obtained
with virtually no change in glaucoma medications in either
group.
At 12 months, IOP reduction was sustained in both groups
with a mean IOP of 19.0 mm Hg (SD, 5.6 mm Hg) in group 1
FIGURE 2. Flow chart.
TABLE 2. Patient Ocular Characteristics
N (%) Group 1, n ¼ 24 Group 2, n ¼ 28 P Value
No. of previous filtering glaucoma surgeries 0.466*
n ¼ 1 15 (62.5) 17 (60.7)
n ¼ 2 6 (25.0) 10 (35.7)
n ‡ 3 3 (12.5) 1 (3.6)
Lens status 0.887*
Phakic 11 (45.8) 15 (53.6)
Pseudophakic 12 (50.0) 12 (42.8)
Aphakic 1 (4.2) 1 (3.6)
Preoperative mean values (range)
IOP, mean 6 SD, mm Hg 29.7 6 7.7 29.0 6 7.4 0.739†
No. of glaucoma medications, eyedrops 2.9 (1–4) 2.8 (0–4) 0.776†
No. of patients with preoperative systemic carbonic anhydrase inhibitors 7 (29.1) 7 (25.0) 0.735‡
No. of previous glaucoma surgeries 1.54 (1–4) 1.50 (1–4) 0.847†
BCVA, logMAR 0.98 0.94 0.899†
* Fisher test.
† Student’s t-test.
‡ v2 test.
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POAG patients (32.0% IOP reduction) and a mean IOP of 19.0
mm Hg (SD, 6 mm Hg) in group 2 POAG patients (33.9% IOP
reduction).
Success, defined as an IOP decrease greater than 20% and
IOP > 5 mm Hg was achieved at 6 months in 78.6% (11/14) of
group 1 POAG patients and 61.9% (13/21) of group 2 POAG
patients. This difference was not statistically significant (Fisher
test, P value ¼ 0.46).
At 12 months, this proportion was 78.6% in group 1 POAG
patients (11/14) and 45.0% in group 2 POAG patients (9/20).
This difference was not statistically significant (Fisher test, P
value ¼ 0.079).
Tolerance
Safety information was reported for 52 subjects, including the
two patients for whom the treatment was not administered as
per protocol.
Intraoperative Complications
Few minor intraoperative complications were reported. As
mentioned above, 38 patients received the procedure under
peribulbar anesthesia, 7 under topical anesthesia, and 7 under
general anesthesia. A total of 4 of 52 patients reported tolerable
pain during the procedure (one patient in group 1 and three
patients in group 2). In all cases, intraoperative pain was
transient and disappeared immediately at the end of the
procedure. Two subjects had intraoperative subconjunctival
hemorrhage.
One patient in group 1 presented an IOP spike of 8 mm Hg
above baseline, which resolved within 1 hour of instillation of
apraclonidine hydrochloride (Iopidine 0.5%; Alcon Laborato-
ries).
No corneal burns were observed during the procedure.
Postoperative Complications
The postoperative complications are listed in Table 5.
Seventeen cases (33%) of superficial punctate keratitis resolved
spontaneously in a few days and two cases of blepharitis were
also reported. Other minor events reported included conjunc-
tival hyperemia for 25 patients (48%), 9 in group 1 and 16 in
group 2; transient anterior chamber uveal reaction in 13
patients, 6 in group 1 and 7 in group 2; and transient corneal
edema for 4 patients (7.7%), 2 in group 1 and 2 in group 2.
Only one patient belonging to group 2 presented transitory
postoperative hypotony (IOP ¼ 4 mm Hg), associated with
choroidal detachment. Antiglaucoma drugs were tapered off,
additional topical steroid treatment was given, and the event
resolved within 30 days.
Lastly, 12 patients required a secondary glaucoma surgical
intervention for insufficient response of HIFU treatment, 9
with trabeculectomy, 2 with diode laser cyclodestruction, and
1 with Ahmed valve surgery. These treatments occurred
between 6 and 12 months after the HIFU procedure. The
study protocol design stated that if an additional treatment
such as filtering surgery or cyclodestruction (CPC laser or
cryotherapy) was administered, the patient would be consid-
ered as having failed the HIFU treatment (failure) and would be
withdrawn from the study. Thus, efficacy data (IOP values)
were not collected and integrated into the results for the
patients withdrawn from the study after undergoing filtering
surgery or CPC treatment by diode laser so as not to bias the
results. This treatment was performed in 12 patients before the
protocol visit planned twelve months after the procedure (four
patients in group 1 and eight patients in group 2).
There was one report of transient macular edema in a group
2 patient, appearing 1 month after the HIFU procedure,
resolving after 1 month under topical nonsteroidal anti-
inflammatory agents with no impact on visual acuity. There
was no report of treatment-induced cataract.
Visual Outcomes
Mean visual acuity remained statistically unchanged (BCVA
logMAR of 0.98 6 1.20 and 1.09 6 1.18 before and at last
follow-up in group 1, respectively; and 0.94 6 1.18 and 1.24 6
1.36 before and at last follow-up in group 2, respectively).
Six patients presented with a loss of BCVA of more than two
lines: three in group 1 (3/24, 12.5%) and three in group 2 (3/
28, 10.7%).
TABLE 5. Intra- and Postoperative Ocular Complications
Ocular Complications Group 1 Group 2
Intraoperative
Pain 1 3
Corneal burn 0 0
Subconjunctival hemorrhage 1 1
Postoperative
Hyperemia 9 16
Superficial punctuated keratitis 6 11
Corneal edema 2 2
Ocular pain 1 2
Anterior chamber reaction 6 7
Transient hypotonia, choroidal detachment 0 1
Transient macular edema 0 1
Phthisis 0 0
Cataract 0 0
Intravitreous hemorrhage 0 0
Loss of visual acuity (>2 lines) 3 (12.5%) 3 (10.7%)
FIGURE 3. Mean IOP per group for the 12 months after HIFU treatment.
Glaucoma Treatment With HIFU IOVS j February 2015 j Vol. 56 j No. 2 j 1094
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/933680/ on 10/26/2015
In group 1, loss of BCVA in two patients was deemed
unrelated to the study treatment (one case of cataract
worsening after vitrectomy for retinal detachment and one
case of central venous occlusion at 12 months).
In group 2, one patient who experienced a loss of BCVA
underwent corneal decompensation of his corneal graft and
one patient presented reactivation of toxoplasmosis choroiditis
1 month after the procedure.
DISCUSSION
Two recent previous studies17,19 have been conducted with
this new device for ultrasound circular cyclocoagulation. The
initial pilot study examined patients with refractory primary or
secondary glaucoma (at least one previous incisional glaucoma
surgery) and limited residual visual acuity and visual field
(BCVA < 20/60; visual field defect located in the paracentral
region).17 The patients included have POAG, neovascular
glaucoma, congenital glaucoma, primary angle-closure glauco-
ma, and iridocorneal endothelial glaucoma. Intraocular pres-
sure is reduced from a mean preoperative value of 37.9 6 10.7
mm Hg to a mean postoperative value of 26.3 6 5.1 mm Hg at
6 months and 24.7 6 8.5 mm Hg at the last follow-up visit. A
33.9% IOP reduction has been obtained at the last follow-up
visit. Surgical success (defined by IOP reduction ‡ 20% and
IOP > 5 mm Hg) has been obtained in 10 of 12 patients
(83.3%) at the last visit. The second study was conducted in 28
patients with POAG and much less advanced disease.19
Intraocular pressure is reduced from a mean preoperative
value of 29.0 6 7.2 mm Hg to a mean value of 21.6 6 9.4 mm
Hg at last follow-up (n ¼ 1.29 procedures) (mean IOP
reduction, 26%). Complete success (IOP reduction > 20%
without reintervention and without additional hypotensive
medications) has been achieved in 50% of eyes at the last
follow-up (mean IOP reduction 45% in these eyes) and
qualified success (IOP reduction > 20% and IOP > 5 mm Hg
with possible reinterventions) has been achieved in 68% of
eyes at the last follow-up.
The present study was designed and conducted to evaluate
the efficacy and safety of ultrasonic circular cyclocoagulation
in patients with both primary and secondary glaucoma and
with two different exposure times in a larger multicenter
clinical trial.
Fifty-two patients with POAG or secondary glaucoma were
enrolled and followed up during at least 12 months. In the 4-
second exposure time group, IOP was reduced from a mean
preoperative value of 29.7 6 7.7 mm Hg to a mean value of
20.1 6 6.7 mm Hg and success (IOP reduction > 20% and IOP
> 5 mm Hg with possible retreatment) was achieved in 57.1%
of eyes at 1 year of follow-up. In the subgroup of POAG
patients, IOP was reduced from a mean preoperative value of
28.0 6 5.0 mm Hg to a mean value of 19.0 6 5.6 mm Hg and
success was achieved in 78.6% of eyes at 1 year of follow-up.
In the 6-second exposure time group, IOP was reduced from a
mean preoperative value of 29.0 6 7.4 mm Hg to a mean
value of 18.5 6 6.6 mm Hg and success (IOP reduction > 20%
and IOP > 5 mm Hg with possible retreatment) was achieved
in 48% of eyes at 1 year of follow-up. In the subgroup of
patients with POAG, IOP was reduced from a mean
preoperative value of 28.7 6 6.8 mm Hg to a mean value of
19.0 6 6.0 mm Hg and success was achieved in 45% of eyes at
1 year of follow-up.
We found lower efficacy in patients with secondary
glaucoma. One explanation could be that the amount of
ciliary body tissue coagulated and the related decrease in
aqueous humor production was sometimes insufficient,
particularly in patients with secondary glaucoma. Since
patients with secondary glaucoma could have a lower
trabecular meshwork outflow of aqueous humor, a similar
decrease in aqueous production could have a lesser effect
on IOP. Some patients with an IOP response insufficient to
reach the target IOP were re-treated. The six transducers
were activated and the probe was rotated with the intention
of targeting different areas of the ciliary body. The diameter
of the probe was generally changed for the second treatment
(n ¼ 3/8 eyes re-treated without diameter change, 4/8
increased, 1/8 decreased). Intraocular pressure decreased
significantly for three eyes after retreatment. This finding
could corroborate the hypothesis that the amount of ciliary
body tissue treated during the first procedure may be
insufficient.
Animal studies conducted with the device have shown
circumferentially distributed coagulation necrosis of the ciliary
processes and ciliary body, particularly with a complete loss of
the ciliary epithelium, likely resulting in reduced aqueous
production. However, UBM examinations performed before
and after the treatment in the first clinical studies have also
shown hyporeflective suprachoroidal fluid spaces in patients
having significantly lower IOP than those without visible
suprachoroidal space, suggesting that ultrasound cyclocoagu-
lation could also increase the uveoscleral outflow through the
supraciliary and suprachoroidal space. The amount of ciliary
body tissue destroyed, and therefore probably the reduction of
aqueous production, increases with increasing dose. In
contrast, one possibility would be that the relationship
between the dose and the effect on the uveoscleral pathway
may not be linear. We can hypothesize that exposure to a small
dose of ultrasound energy leads to tissue retraction or tissue
microarchitecture changes increasing the permeability to
aqueous humor, whereas greater exposure to ultrasound
energy coagulates the uveoscleral tract and decreases the
related aqueous outflow. A more definitive answer would
require in vivo fluorophotometric and tonographic quantifica-
tion of the aqueous inflow and outflow with various exposure
times.
FIGURE 4. Ocular tolerance: Slit-lamp photographs taken preoperatively on the day before (left), 1 day after (middle), and 8 days after the
procedure (right) (4-second HIFU treatment).
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The tolerability of HIFU cyclocoagulation was good in the
present study, as reported in the two previous studies, with no
IOP spikes or major IOP increases during the early follow-up
and over the long term no cases of severe hypotony or phthisis,
which are some of the most serious adverse effects of the
currently available cyclodestructive methods. Clinical exami-
nations showed little or no signs of intraocular inflammation
(Figs. 4, 5) and visual acuity remained statistically unchanged in
most of the patients.
CONCLUSIONS
In summary, the present multicenter study showed that
ultrasonic coagulation of the ciliary body, using high-intensity
focused ultrasound, is effective in decreasing IOP, particularly
in patients with POAG. A substantial increase in ultrasound
exposure time does not seem to increase the rate of responders
and the global efficacy of the technique.
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FIGURE 5. Image showing localized and nontransilluminable scleral
thinning after ultrasound circular cyclo-coagulation (UC3) cyclophoto-
coagulation. Note that the regions appear to be well delineated,
without any signs of conjunctival inflammation, induced corneal
astigmatism, or scleral protrusion. Black arrow indicates area on 7-
o’clock meridian treated.
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